Fate Therapeutics Inc. (NASDAQ:FATE)’s share price was down 2.4% on Monday . The stock traded as low as $2.82 and last traded at $2.85, with a volume of 183,154 shares changing hands. The stock had previously closed at $2.92.

Several equities analysts have recently weighed in on FATE shares. HC Wainwright restated a “buy” rating on shares of Fate Therapeutics in a research report on Tuesday, August 9th. Zacks Investment Research lowered shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th. Leerink Swann restated an “outperform” rating and set a $4.00 price objective on shares of Fate Therapeutics in a research report on Tuesday, June 21st. Finally, BMO Capital Markets restated an “outperform” rating and set a $4.00 price objective on shares of Fate Therapeutics in a research report on Tuesday, June 21st. Eight analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $6.29.

The stock’s market capitalization is $92.17 million. The company’s 50 day moving average price is $2.62 and its 200-day moving average price is $2.02.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.03. The company earned $1.03 million during the quarter, compared to analysts’ expectations of $1.02 million. Fate Therapeutics had a negative return on equity of 90.94% and a negative net margin of 699.10%. On average, equities research analysts predict that Fate Therapeutics Inc. will post ($1.12) EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of FATE. BlackRock Institutional Trust Company N.A. boosted its position in shares of Fate Therapeutics by 66.0% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 69,394 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 27,578 shares during the last quarter. Spark Investment Management LLC boosted its position in shares of Fate Therapeutics by 1.8% in the first quarter. Spark Investment Management LLC now owns 63,700 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,100 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Fate Therapeutics by 151.6% in the first quarter. Renaissance Technologies LLC now owns 222,700 shares of the biopharmaceutical company’s stock worth $401,000 after buying an additional 134,200 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of Fate Therapeutics by 448.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 204,447 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 167,194 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Fate Therapeutics by 7.8% in the second quarter. Bank of New York Mellon Corp now owns 68,444 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 4,941 shares during the last quarter. 48.71% of the stock is owned by institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

5 Day Chart for NASDAQ:FATE

Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.